|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts显示文摘AIM: To evaluate the efficacy and safety of the FOLFIRI regimen in patients with metastatic pancreatic adenocarcinoma (PAC) after the failure of gemcitabine and platinum salts. METHODS: All consecutive patients with histologically confirmed, metastatic PAC and World Health Organiza-tion performance status (PS) ≤ 2 received FOLFIRI-1 [irinotecan 180 mg/m2 on day 1 and leucovorin 400 mg/m2 followed by 5-fluorouracil (5-FU) 400 mg/m2 bolus, then 5-FU 2400 mg/m2 as a 46-h infusion, biweekly] or FOLFIRI-3 (irinotecan 100 mg/m2 on day 1 and leucovorin 400 mg/m2, then 5-FU 2400 mg/m2 as a 46-h infusion and irinotecan 100 mg/m2 repeated on day 3, biweekly) after failure of gemcitabine and platinum-based chemotherapies as a systematic policy in two institutions between January 2005 and May 2010. Tumor response, time to progression (TTP), overall survival rate (OS) and grade 3-4 toxicities were retrospectively studied. Subgroup analyses were performed to search for prognostic factors. RESULTS: Sixty-three patients (52.4% male, median age 59 years) were analyzed. Among them, 42.9% were PS 0, 38.1% were PS 1 and 19.0% were PS 2. Fifty one patients (81.0%) had liver metastases. Before the FOLFIRI regimen, patients had received 1 line (n = 19), 2 lines (n = 39) or 3 lines (n = 5) of chemotherapy. Median TTP obtained with the line before FOLFIRI was 3.9 mo (95% CI: 3.4-5.3 mo). A total of 480 cycles was completed (median: 6 cycles, range: 1-51 cycles). The main reason for discontinuing FOLFIRI was tumor progression (90.3%). Tumor control was achieved in 25 patients (39.7%) (partial response: n = 5, stable disease: n = 20) with FOLFIRI. Median TTP was 3.0 mo (95% CI: 2.1-3.9 mo) and median OS was 6.6 mo (95% CI: 5.3-8.1 mo). Dose adaptation was required in 36 patients (57.1%). Fifteen patients (23.8%) had grade 3-4 toxicities, mainly hematological (n = 11) or digestive (n = 4). Febrile neutropenia occurred in 3 patients. There was no toxic death. PS 2 was significantly associated with poor TTP [hazard ratio (HR): 16.036, P < 0.0001] and OS (HR: 4.003, P = 0.004). CONCLUSION: The FOLFIRI regimen had an acceptable toxicity and an interesting efficacy in our study, limited to patients in good condition (PS 0-1). | Cindy Neuzillet Olivia Hentic Benot Rousseau Vinciane Rebours Léla Bengrine-Lefèvre Franck Bonnetain Philippe Lévy Eric Raymond Philippe Ruszniewski Christophe Louvet Pascal Hammel | 2012 | World Journal of Gastroenterology2012，18，33： | 3 |
| 2 | Splenic and portal venous obstruction in chronic pancreatitis显示文摘 | Pr. Pierre Bernades André Baetz Philippe Lévy Jacques Belghiti Yves Menu Fran?ois Fékété | 1992 | Digestive Diseases and Sciences1992，，3： | 2 |
| 3 | At the center of eukaryotic life显示文摘 | Moss T Stefanovsky VY | 2002 | Cell2002，109，5： | 1 |
| 4 | Impaired IL - 18 processing protects caspase 1 deficiet mice from isch emic acute renal failure 显示文摘 | M elnikov VY E cder T Fan tuzz iG | 2001 | J C 1 in Invest2001，107，9： | 1 |
| 5 | Impaired ulL- 18 pro- eessing protects caspase - 1 - deficient mice from isehemic acute renal failure显示文摘 | Melnikov VY Ecder T Fantuzzi G | 2001 | J Clin Invest2001，107，9： | 1 |
| 6 | An atherogenic diet decreases liver FXR gene expression and causes severe hepatic steatosis and hepatic cholesterol accumulation:effect of endurance training显示文摘 | C(o)té I Sock ETN Lévy (E) Lavoie J-M | | 0，，： | 1 |
| 7 | At the center of eukaryotic life显示文摘 | Moss T Stefanovsky VY | 2002 | Cell2002，109，5： | 1 |
| 8 | Impaired IL-18 process-ing protects caspase-1-deficient mice from ischemic acute renalfailure显示文摘 | Melnikov VY Ecder T Fantuzzi G | 2001 | J Clin Invest2001，107，9： | 1 |
| 9 | Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma 显示文摘 | Yah T Tang VY Yao TJ | 2014 | Gastroenterology2014，146，16： | 1 |
| 10 | Development of Hong Kong Liver Cancer staging system with treatment stratifi- cation for patients with hepatocellular carcinoma 显示文摘 | Yau T Tang VY Yao TJ | 2014 | Gas- troenterology2014，146，7： | 1 |
| 11 | Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure显示文摘 | Melnikov VY Ecder T Fantuzzi G | | 0，，： | 1 |
| 12 | Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure显示文摘 | Melnikov VY Ecder T Fantuzzi G | 2001 | J Clin Invest2001，107，9： | 1 |
| 13 | Inhibition of growth hormone signaling by the fasting-induced hormone FGF21显示文摘 | Inaguki T Lin VY Gostz It | 2008 | Cell Metab2008，8，： | 1 |
| 14 | Impaired IL- 18 processing protects caspase - 1-deficient mice from ischemic acute renal failure显示文摘 | Melnikov VY Ecder T Fantuzzi G | 2001 | J Clin Invest2001，107，： | 1 |
| 15 | Impaired IL-18 process- ing protects caspase-l-deficient mice from ischemic acute renal fail- ure显示文摘 | Melnikov VY Ecder T Fantuzzi G | 2001 | J Clin Invest2001，107，9： | 1 |
| 16 | Splenic and portal venous obstruction in chronic pancreatitis显示文摘 | Pr. Pierre Bernades André Baetz Philippe Lévy Jacques Belghiti Yves Menu Fran?ois Fékété | 1992 | Digestive Diseases and Sciences1992，，3： | 1 |
| 17 | At the center of eukaryotic life 显示文摘 | Moss T Stefanovsky VY | 2002 | Cen2002，，109： | 1 |
| 18 | P r e d i c t o r s o f bronchopulmonary dysplasia or death in premature infants with a patent ductus arteriosus显示文摘 | Chock VY P u n n R O z a A e t a l | 2014 | Pediatr Res2014，75，4： | 1 |
| 19 | Total variation regulated EM algorithm显示文摘 | Panin VY Zeng GL Gullberg G T | 1999 | IEEE Trans Nucl Sci1999，46，： | 1 |
| 20 | Impaired IL-18 processingprotects caspase-1-deficient mice from ischemic acute renal failure显示文摘 | Melnikov VY Ecder T Fantuzzi G | 2001 | Clin Invest2001，107，9： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员